Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia
- 1 March 2016
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 16 (3) , 169-174
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin CNew England Journal of Medicine, 2012
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibJNCI: Journal of the National Cancer Institute, 2011
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion ProteinsMolecular Cancer Therapeutics, 2011
- Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphismsAmerican Journal of Physiology-Renal Physiology, 2010
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Predictive Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Estimating Renal FunctionJournal of the American Society of Nephrology, 2005
- A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?Journal of Internal Medicine, 1999
- Creatinine clearance during cimetidine administration for measurement of glomerular filtration rateThe Lancet, 1992
- Measurement of renal function in chronic renal diseaseKidney International, 1990
- Limitations of creatinine as a filtration marker in glomerulopathic patientsKidney International, 1985